Ask VialBase
weight · loss

Cagrilintide

Also known as: AM833, NNC0174-0833
FDA: Not FDA-approved WADA: Not specifically listed
Last updated · 2026-06-19

Cagrilintide (AM833 / NNC0174-0833) is a long-acting, once-weekly amylin analog developed by Novo Nordisk and a dual amylin and calcitonin receptor agonist (DACRA). It is the long-acting successor to Pramlintide (the first amylin analog, which required TID dosing) and is best known as the amylin half of CagriSema, its fixed-dose combination with Semaglutide. Mechanistically it sits in a different class from GLP-1/incretin drugs (Semaglutide, Tirzepatide, Retatrutide) — which is precisely why pairing it with semaglutide produces additive weight loss. Unlike most peptides in this vault, cagrilintide has a real, peer-reviewed human RCT program (Phase 1b → Phase 2 → Phase

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight ~3700
Half-life ~7 days ~159-195
CAS number —
Route Subcutaneous
Where to buy Cagrilintide →Certified-Pep
02

Dosing

DOSE RANGE 300–4500 mcg
FREQUENCY 1x weekly
CYCLE LENGTH Ongoing (titrate slowly over weeks to 2.4mg maintenance)

Phase 3 / CagriSema maintenance dose is 2.4mg weekly SubQ, reached by gradual titration to limit GI side effects. Phase 2 monotherapy tested 0.3-4.5mg. Amylin analogs are fibrillation-prone — formulation/handling quality matters. No approved consumer dose.

03

Mechanism

Long-acting amylin analog and dual amylin and calcitonin receptor agonist (DACRA). Activates amylin/calcitonin receptor complexes (CTR + RAMP1/2/3 = AMY1/2/3) in the area postrema, dorsal vagal complex, and hypothalamus to increase satiety, slow gastric emptying, and suppress post-meal glucagon. Distinct from the GLP-1/GIP incretin pathway — the rationale for combining with semaglutide as CagriSema.

04

Stacking & interactions

Core pairing (= CagriSema). Amylin agonism + GLP-1 agonism = additive appetite suppression via parallel pathways. Drives ~20-23% weight loss vs ~16% sema alone.

Gut protection during GLP-1/amylin-mediated GI side effects (research context)

05

Sourcing

Current prices

Updated today

10mg

Only vendor stocking this size on the VialBase roster.

Stocks this compound Third-party tested Public COAs

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC
  • Lipid Panel
  • Fasting Glucose
  • HbA1c
  • Fasting Insulin
  • Amylase
  • Lipase
DURING CYCLE
  • Fasting Glucose
  • HbA1c
  • Lipid Panel
  • Amylase
  • Lipase
POST-CYCLE
  • CMP
  • Lipid Panel
  • Fasting Glucose
  • HbA1c
Safety & Regulatory Status
FDA STATUS Not FDA-approved. Investigational. Best known as the amylin component of CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg). Novo Nordisk filed CagriSema NDA with FDA on 2025-12-18; decision expected ~late 2026. Stand-alone cagrilintide never submitted for approval.
WADA STATUS Not specifically listed (covered under S0 as non-approved substance)

Regulatory status for Cagrilintide may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

Frequently Asked Questions

What is Cagrilintide?
Cagrilintide (AM833) is a long-acting, once-weekly amylin analog developed by Novo Nordisk and classified as a dual amylin and calcitonin receptor agonist (DACRA). It is best known as the amylin half of CagriSema, its fixed-dose combination with semaglutide. It remains investigational and is not FDA-approved in any form. Unusually for a peptide in this space, it has a real human RCT program.
How does Cagrilintide work?
Cagrilintide mimics amylin, a hormone co-secreted with insulin after meals that controls satiety. It activates amylin receptors (calcitonin receptor plus RAMP complexes) in the brainstem and hypothalamus to increase fullness, and engages the calcitonin receptor directly (the "dual" in DACRA). It also slows gastric emptying and blunts post-meal glucagon. Engineering gives it a roughly 7-day half-life for weekly dosing.
How is Cagrilintide dosed?
In trials cagrilintide is given subcutaneously once weekly, titrated slowly (about every four weeks) to a 2.4 mg maintenance dose — the CagriSema dose — to limit nausea; Phase 2 monotherapy tested up to 4.5 mg. There is no approved consumer dose, and only gray-market supply exists. These are research figures, not medical advice — consult a clinician.
What does the research on Cagrilintide show?
The evidence tier is human RCTs in top journals. In a Phase 2 monotherapy trial, cagrilintide produced dose-dependent weight loss up to about 10.8% at 26 weeks (Lau et al., Lancet 2021, PMID 34798060). In the Phase 3 REDEFINE 1 trial, CagriSema reached roughly 20–23% weight loss versus about 16% for semaglutide alone (Garvey et al., NEJM 2025, PMID 40544433). It remains investigational.
What is CagriSema and how does it differ from cagrilintide alone?
CagriSema is the fixed-dose combination of cagrilintide and semaglutide (2.4 mg each). Cagrilintide works through the amylin/calcitonin pathway while semaglutide is a GLP-1 agonist; a Phase 1b study confirmed no pharmacokinetic interaction, so their appetite effects are additive (Enebo et al., Lancet 2021, PMID 33894838). The headline 20%+ weight-loss figures belong to CagriSema, not stand-alone cagrilintide (about 10–12%).
What are the side effects of Cagrilintide?
Side effects are predominantly gastrointestinal and concentrated during dose titration: nausea, vomiting, diarrhea, constipation, and reduced appetite. In the Phase 3 REDEFINE 1 trial, GI events occurred in about 80% on CagriSema versus 40% on placebo, but treatment discontinuation was low (around 6%). Class concerns include pancreatitis and gallbladder disease; most safety data come from the combination, not cagrilintide alone.
Is Cagrilintide FDA-approved?
No. Cagrilintide is not FDA-approved in any form, and stand-alone cagrilintide was never submitted for approval. Novo Nordisk filed the CagriSema NDA on December 18, 2025, with an FDA decision expected around late 2026. It is not eligible for pharmacy compounding, and only gray-market research-chemical supply exists, which carries purity and dosing-accuracy risks.